应用动态[18F]FDG PET/CT 多参数成像改进良性和恶性肺部病变的鉴别。

IF 3 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Molecular Imaging and Biology Pub Date : 2024-10-01 Epub Date: 2024-08-22 DOI:10.1007/s11307-024-01942-w
Yihan Zhao, Tao Lv, Yue Xu, Jiankang Yin, Xin Wang, Yangyang Xue, Gan Zhu, Wenjing Yu, Hui Wang, Xiaohu Li
{"title":"应用动态[18F]FDG PET/CT 多参数成像改进良性和恶性肺部病变的鉴别。","authors":"Yihan Zhao, Tao Lv, Yue Xu, Jiankang Yin, Xin Wang, Yangyang Xue, Gan Zhu, Wenjing Yu, Hui Wang, Xiaohu Li","doi":"10.1007/s11307-024-01942-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the potential of whole-body dynamic (WBD) 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose positron emission tomography/computed tomography ([<sup>18</sup>F]FDG PET/CT) multiparametric imaging in the differential diagnosis between benign and malignant lung lesions.</p><p><strong>Procedures: </strong>We retrospectively analyzed WBD PET/CT scans from patients with lung lesions performed between April 2020 and March 2023. Multiparametric images including standardized uptake value (SUV), metabolic rate (MR<sub>FDG</sub>) and distribution volume (DV<sub>FDG</sub>) were visually interpreted and compared. We adopted SUV<sub>max</sub>, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) for semi-quantitative analysis, MR<sub>max</sub> and DV<sub>max</sub> values for quantitative analysis. We also collected the patients' clinical characteristics. The variables above with P-value < 0.05 in the univariate analysis were entered into a multivariate logistic regression. The statistically significant metrics were plotted on receiver-operating characteristic (ROC) curves.</p><p><strong>Results: </strong>A total of 60 patients were included for data evaluation. We found that most malignant lesions showed high uptake on MR<sub>FDG</sub> and SUV images, and low or absent uptake on DV<sub>FDG</sub> images, while benign lesions showed low uptake on MR<sub>FDG</sub> images and high uptake on DV<sub>FDG</sub> images. Most malignant lesions showed a characteristic pattern of gradually increasing FDG uptake, whereas benign lesions presented an initial rise with rapid fall, then kept stable at a low level. The AUC values of MR<sub>max</sub> and SUV<sub>max</sub> are 0.874 (95% CI: 0.763-0.946) and 0.792 (95% CI: 0.667-0.886), respectively. DeLong's test showed the difference between the areas is statistically significant (P < 0.001).</p><p><strong>Conclusions: </strong>Our study demonstrated that dynamic [<sup>18</sup>F]FDG PET/CT imaging based on the Patlak analysis was a more accurate method of distinguishing malignancies from benign lesions than conventional static PET/CT scans.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"790-801"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Application of Dynamic [<sup>18</sup>F]FDG PET/CT Multiparametric Imaging Leads to an Improved Differentiation of Benign and Malignant Lung Lesions.\",\"authors\":\"Yihan Zhao, Tao Lv, Yue Xu, Jiankang Yin, Xin Wang, Yangyang Xue, Gan Zhu, Wenjing Yu, Hui Wang, Xiaohu Li\",\"doi\":\"10.1007/s11307-024-01942-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the potential of whole-body dynamic (WBD) 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose positron emission tomography/computed tomography ([<sup>18</sup>F]FDG PET/CT) multiparametric imaging in the differential diagnosis between benign and malignant lung lesions.</p><p><strong>Procedures: </strong>We retrospectively analyzed WBD PET/CT scans from patients with lung lesions performed between April 2020 and March 2023. Multiparametric images including standardized uptake value (SUV), metabolic rate (MR<sub>FDG</sub>) and distribution volume (DV<sub>FDG</sub>) were visually interpreted and compared. We adopted SUV<sub>max</sub>, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) for semi-quantitative analysis, MR<sub>max</sub> and DV<sub>max</sub> values for quantitative analysis. We also collected the patients' clinical characteristics. The variables above with P-value < 0.05 in the univariate analysis were entered into a multivariate logistic regression. The statistically significant metrics were plotted on receiver-operating characteristic (ROC) curves.</p><p><strong>Results: </strong>A total of 60 patients were included for data evaluation. We found that most malignant lesions showed high uptake on MR<sub>FDG</sub> and SUV images, and low or absent uptake on DV<sub>FDG</sub> images, while benign lesions showed low uptake on MR<sub>FDG</sub> images and high uptake on DV<sub>FDG</sub> images. Most malignant lesions showed a characteristic pattern of gradually increasing FDG uptake, whereas benign lesions presented an initial rise with rapid fall, then kept stable at a low level. The AUC values of MR<sub>max</sub> and SUV<sub>max</sub> are 0.874 (95% CI: 0.763-0.946) and 0.792 (95% CI: 0.667-0.886), respectively. DeLong's test showed the difference between the areas is statistically significant (P < 0.001).</p><p><strong>Conclusions: </strong>Our study demonstrated that dynamic [<sup>18</sup>F]FDG PET/CT imaging based on the Patlak analysis was a more accurate method of distinguishing malignancies from benign lesions than conventional static PET/CT scans.</p>\",\"PeriodicalId\":18760,\"journal\":{\"name\":\"Molecular Imaging and Biology\",\"volume\":\" \",\"pages\":\"790-801\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Imaging and Biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11307-024-01942-w\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-024-01942-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

目的:评估全身动态(WBD)2-脱氧-2-[18F]氟-D-葡萄糖正电子发射断层扫描/计算机断层扫描([18F]FDG PET/CT)多参数成像在肺部良性和恶性病变鉴别诊断中的潜力:我们对2020年4月至2023年3月期间肺部病变患者的WBD PET/CT扫描进行了回顾性分析。对包括标准化摄取值(SUV)、代谢率(MRFDG)和分布容积(DVFDG)在内的多参数图像进行了视觉解读和比较。我们采用 SUVmax、代谢肿瘤体积(MTV)和总病变糖酵解(TLG)进行半定量分析,采用 MRmax 和 DVmax 值进行定量分析。我们还收集了患者的临床特征。上述变量的 P 值 结果:共纳入 60 名患者进行数据评估。我们发现,大多数恶性病变在 MRFDG 和 SUV 图像上显示高摄取,而在 DVFDG 图像上显示低摄取或无摄取;良性病变在 MRFDG 图像上显示低摄取,而在 DVFDG 图像上显示高摄取。大多数恶性病变表现出 FDG 摄取量逐渐升高的特征,而良性病变则表现为最初升高后迅速下降,然后稳定在较低水平。MRmax 和 SUVmax 的 AUC 值分别为 0.874(95% CI:0.763-0.946)和 0.792(95% CI:0.667-0.886)。DeLong检验表明,两个区域之间的差异具有统计学意义(P 结论:我们的研究表明,动态[18FS]瘤细胞的钙化率为0.5%:我们的研究表明,与传统的静态 PET/CT 扫描相比,基于 Patlak 分析的动态[18F]FDG PET/CT 成像是一种更准确的区分恶性肿瘤和良性病变的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Application of Dynamic [<sup>18</sup>F]FDG PET/CT Multiparametric Imaging Leads to an Improved Differentiation of Benign and Malignant Lung Lesions.

Application of Dynamic [18F]FDG PET/CT Multiparametric Imaging Leads to an Improved Differentiation of Benign and Malignant Lung Lesions.

Purpose: To evaluate the potential of whole-body dynamic (WBD) 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) multiparametric imaging in the differential diagnosis between benign and malignant lung lesions.

Procedures: We retrospectively analyzed WBD PET/CT scans from patients with lung lesions performed between April 2020 and March 2023. Multiparametric images including standardized uptake value (SUV), metabolic rate (MRFDG) and distribution volume (DVFDG) were visually interpreted and compared. We adopted SUVmax, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) for semi-quantitative analysis, MRmax and DVmax values for quantitative analysis. We also collected the patients' clinical characteristics. The variables above with P-value < 0.05 in the univariate analysis were entered into a multivariate logistic regression. The statistically significant metrics were plotted on receiver-operating characteristic (ROC) curves.

Results: A total of 60 patients were included for data evaluation. We found that most malignant lesions showed high uptake on MRFDG and SUV images, and low or absent uptake on DVFDG images, while benign lesions showed low uptake on MRFDG images and high uptake on DVFDG images. Most malignant lesions showed a characteristic pattern of gradually increasing FDG uptake, whereas benign lesions presented an initial rise with rapid fall, then kept stable at a low level. The AUC values of MRmax and SUVmax are 0.874 (95% CI: 0.763-0.946) and 0.792 (95% CI: 0.667-0.886), respectively. DeLong's test showed the difference between the areas is statistically significant (P < 0.001).

Conclusions: Our study demonstrated that dynamic [18F]FDG PET/CT imaging based on the Patlak analysis was a more accurate method of distinguishing malignancies from benign lesions than conventional static PET/CT scans.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.90
自引率
3.20%
发文量
95
审稿时长
3 months
期刊介绍: Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信